ATE346601T1 - Verwendung von antidiabetika zur herstellung eines vernarbungsfördernden arzneimittels - Google Patents
Verwendung von antidiabetika zur herstellung eines vernarbungsfördernden arzneimittelsInfo
- Publication number
- ATE346601T1 ATE346601T1 AT02748965T AT02748965T ATE346601T1 AT E346601 T1 ATE346601 T1 AT E346601T1 AT 02748965 T AT02748965 T AT 02748965T AT 02748965 T AT02748965 T AT 02748965T AT E346601 T1 ATE346601 T1 AT E346601T1
- Authority
- AT
- Austria
- Prior art keywords
- scaring
- production
- medicinal product
- antidiabetic drugs
- promoting medicinal
- Prior art date
Links
- 239000003472 antidiabetic agent Substances 0.000 title abstract 2
- 229940127003 anti-diabetic drug Drugs 0.000 title 1
- 229940126601 medicinal product Drugs 0.000 title 1
- 230000001737 promoting effect Effects 0.000 title 1
- 239000003112 inhibitor Substances 0.000 abstract 2
- NOESYZHRGYRDHS-UHFFFAOYSA-N insulin Chemical compound N1C(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(NC(=O)CN)C(C)CC)CSSCC(C(NC(CO)C(=O)NC(CC(C)C)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CCC(N)=O)C(=O)NC(CC(C)C)C(=O)NC(CCC(O)=O)C(=O)NC(CC(N)=O)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CSSCC(NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2C=CC(O)=CC=2)NC(=O)C(CC(C)C)NC(=O)C(C)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2NC=NC=2)NC(=O)C(CO)NC(=O)CNC2=O)C(=O)NCC(=O)NC(CCC(O)=O)C(=O)NC(CCCNC(N)=N)C(=O)NCC(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC(O)=CC=3)C(=O)NC(C(C)O)C(=O)N3C(CCC3)C(=O)NC(CCCCN)C(=O)NC(C)C(O)=O)C(=O)NC(CC(N)=O)C(O)=O)=O)NC(=O)C(C(C)CC)NC(=O)C(CO)NC(=O)C(C(C)O)NC(=O)C1CSSCC2NC(=O)C(CC(C)C)NC(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CC(N)=O)NC(=O)C(NC(=O)C(N)CC=1C=CC=CC=1)C(C)C)CC1=CN=CN1 NOESYZHRGYRDHS-UHFFFAOYSA-N 0.000 abstract 2
- SWLAMJPTOQZTAE-UHFFFAOYSA-N 4-[2-[(5-chloro-2-methoxybenzoyl)amino]ethyl]benzoic acid Chemical compound COC1=CC=C(Cl)C=C1C(=O)NCCC1=CC=C(C(O)=O)C=C1 SWLAMJPTOQZTAE-UHFFFAOYSA-N 0.000 abstract 1
- 102000004366 Glucosidases Human genes 0.000 abstract 1
- 108010056771 Glucosidases Proteins 0.000 abstract 1
- 102000004877 Insulin Human genes 0.000 abstract 1
- 108090001061 Insulin Proteins 0.000 abstract 1
- 206010022489 Insulin Resistance Diseases 0.000 abstract 1
- 229940124754 PPAR-alpha/gamma agonist Drugs 0.000 abstract 1
- 229940123464 Thiazolidinedione Drugs 0.000 abstract 1
- 230000003178 anti-diabetic effect Effects 0.000 abstract 1
- 239000003795 chemical substances by application Substances 0.000 abstract 1
- 150000001875 compounds Chemical class 0.000 abstract 1
- 239000003814 drug Substances 0.000 abstract 1
- 230000000694 effects Effects 0.000 abstract 1
- 230000002708 enhancing effect Effects 0.000 abstract 1
- 229940125396 insulin Drugs 0.000 abstract 1
- 230000003914 insulin secretion Effects 0.000 abstract 1
- 229950004994 meglitinide Drugs 0.000 abstract 1
- GCYXWQUSHADNBF-AAEALURTSA-N preproglucagon 78-108 Chemical compound C([C@@H](C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](C)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CCCCN)C(=O)NCC(=O)N[C@@H](CCCNC(N)=N)C(=O)NCC(O)=O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CCCCN)NC(=O)[C@H](C)NC(=O)[C@H](C)NC(=O)[C@H](CCC(N)=O)NC(=O)CNC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@H](CO)NC(=O)[C@H](CO)NC(=O)[C@@H](NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CO)NC(=O)[C@@H](NC(=O)[C@H](CC=1C=CC=CC=1)NC(=O)[C@@H](NC(=O)CNC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](C)NC(=O)[C@@H](N)CC=1N=CNC=1)[C@@H](C)O)[C@@H](C)O)C(C)C)C1=CC=CC=C1 GCYXWQUSHADNBF-AAEALURTSA-N 0.000 abstract 1
- 230000000638 stimulation Effects 0.000 abstract 1
- 150000001467 thiazolidinediones Chemical class 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/702—Oligosaccharides, i.e. having three to five saccharide radicals attached to each other by glycosidic linkages
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
- A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
- A61K31/197—Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid or pantothenic acid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/425—Thiazoles
- A61K31/426—1,3-Thiazoles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/425—Thiazoles
- A61K31/427—Thiazoles not condensed and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
- A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/445—Non condensed piperidines, e.g. piperocaine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/445—Non condensed piperidines, e.g. piperocaine
- A61K31/451—Non condensed piperidines, e.g. piperocaine having a carbocyclic group directly attached to the heterocyclic ring, e.g. glutethimide, meperidine, loperamide, phencyclidine, piminodine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/64—Sulfonylureas, e.g. glibenclamide, tolbutamide, chlorpropamide
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/22—Hormones
- A61K38/26—Glucagons
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/22—Hormones
- A61K38/28—Insulins
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/43—Enzymes; Proenzymes; Derivatives thereof
- A61K38/46—Hydrolases (3)
- A61K38/47—Hydrolases (3) acting on glycosyl compounds (3.2), e.g. cellulases, lactases
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Chemical & Material Sciences (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Gastroenterology & Hepatology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Immunology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Endocrinology (AREA)
- Organic Chemistry (AREA)
- General Chemical & Material Sciences (AREA)
- Dermatology (AREA)
- Zoology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Diabetes (AREA)
- Molecular Biology (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Medicinal Preparation (AREA)
- Medicines Containing Plant Substances (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US29919601P | 2001-06-20 | 2001-06-20 | |
| FR0108130A FR2826278B1 (fr) | 2001-06-20 | 2001-06-20 | Utilisation d'agents antidiabetiques pour fabriquer un medicament ayant un effet cicatrisant |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| ATE346601T1 true ATE346601T1 (de) | 2006-12-15 |
Family
ID=26213059
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| AT02748965T ATE346601T1 (de) | 2001-06-20 | 2002-06-19 | Verwendung von antidiabetika zur herstellung eines vernarbungsfördernden arzneimittels |
Country Status (8)
| Country | Link |
|---|---|
| EP (1) | EP1397124B1 (de) |
| AT (1) | ATE346601T1 (de) |
| AU (1) | AU2002319381A1 (de) |
| CY (1) | CY1105822T1 (de) |
| DE (1) | DE60216453T2 (de) |
| DK (1) | DK1397124T3 (de) |
| ES (1) | ES2275889T3 (de) |
| WO (1) | WO2003003971A2 (de) |
Families Citing this family (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| FR2686899B1 (fr) | 1992-01-31 | 1995-09-01 | Rhone Poulenc Rorer Sa | Nouveaux polypeptides biologiquement actifs, leur preparation et compositions pharmaceutiques les contenant. |
| JP2003530838A (ja) | 2000-04-12 | 2003-10-21 | ヒューマン ゲノム サイエンシズ インコーポレイテッド | アルブミン融合タンパク質 |
| ES2425738T3 (es) | 2001-12-21 | 2013-10-17 | Human Genome Sciences, Inc. | Proteínas de fusión de la albúmina |
| DE10214506A1 (de) * | 2002-04-02 | 2003-10-16 | Beiersdorf Ag | Verwendung von Desoxynojirimycin und dessen Derivaten zur Behandlung und Prophylaxe degenerativer Hautzustände |
| EP1594530A4 (de) | 2003-01-22 | 2006-10-11 | Human Genome Sciences Inc | Albuminfusionsproteine |
| GB0303600D0 (en) * | 2003-02-17 | 2003-03-19 | Glaxo Group Ltd | Novel therapeutic method and compositions |
Family Cites Families (13)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US3072527A (en) * | 1959-07-01 | 1963-01-08 | Horner Frank W Ltd | Use of tolbutamide in the treatment of acne |
| DE2401450A1 (de) * | 1973-01-16 | 1974-07-18 | John James Voorhees | Pharmazeutische zusammensetzung zur linderung von hautproliferationserkrankungen |
| US4131652A (en) * | 1977-06-22 | 1978-12-26 | Deluccia Charles R | Medicinal skin cream for psoriasis and method |
| US5145679A (en) * | 1989-10-05 | 1992-09-08 | Hinson Joan B | Topical emollient for prevention and treatment of circulatory induced lesions |
| AU2905092A (en) * | 1991-10-28 | 1993-06-07 | Cytoven | Pharmaceutical dipeptide compositions and methods of use thereof |
| GB9701374D0 (en) * | 1997-01-23 | 1997-03-12 | Univ Liverpool | Purinergic agonists and antagonists |
| US5929055A (en) * | 1997-06-23 | 1999-07-27 | The Research Foundation Of State University Of New York | Therapeutic method for management of diabetes mellitus |
| JP2000212191A (ja) * | 1999-01-26 | 2000-08-02 | Sankyo Co Ltd | リン酸誘導体 |
| CO5200844A1 (es) * | 1999-09-17 | 2002-09-27 | Novartis Ag | Una combinacion que comprende nateglinida y cuando por menos otro compuesto antidiabetico usada para el tratamiento de desordenes metabolicos, especialmente diabetes, o de una enfermedad o condicion asociada con dibetes |
| WO2001026639A2 (en) * | 1999-10-08 | 2001-04-19 | Novartis Ag | Pharmaceutical composition of ateglinide and another antidiabeticagent |
| FR2802814B1 (fr) * | 1999-12-23 | 2002-02-22 | Aventis Pharma Sa | Association de deoxyfructosazine et d'un antidiabetique de la famille des sulfonylurees |
| WO2001076650A1 (en) * | 2000-04-06 | 2001-10-18 | University Technology Corporation | Compositions and methods for promoting wound healing |
| PE20020323A1 (es) * | 2000-08-22 | 2002-06-13 | Novartis Ag | COMPOSICION FARMACEUTICA QUE COMPRENDE UN POTENCIADOR DE LA SECRESION DE INSULINA E INHIBIDORES DE HMG-Co-A-REDUCTASA O INHIBIDORES DE LA ENZIMA CONVERTIDORA DE ANGIOTENSINA (ACE) |
-
2002
- 2002-06-19 EP EP02748965A patent/EP1397124B1/de not_active Expired - Lifetime
- 2002-06-19 WO PCT/FR2002/002124 patent/WO2003003971A2/fr not_active Ceased
- 2002-06-19 AT AT02748965T patent/ATE346601T1/de active
- 2002-06-19 DK DK02748965T patent/DK1397124T3/da active
- 2002-06-19 DE DE60216453T patent/DE60216453T2/de not_active Expired - Lifetime
- 2002-06-19 AU AU2002319381A patent/AU2002319381A1/en not_active Abandoned
- 2002-06-19 ES ES02748965T patent/ES2275889T3/es not_active Expired - Lifetime
-
2006
- 2006-12-04 CY CY20061101738T patent/CY1105822T1/el unknown
Also Published As
| Publication number | Publication date |
|---|---|
| EP1397124B1 (de) | 2006-11-29 |
| DE60216453D1 (de) | 2007-01-11 |
| AU2002319381A1 (en) | 2003-01-21 |
| DK1397124T3 (da) | 2007-04-02 |
| ES2275889T3 (es) | 2007-06-16 |
| WO2003003971A3 (fr) | 2003-12-04 |
| WO2003003971A2 (fr) | 2003-01-16 |
| EP1397124A2 (de) | 2004-03-17 |
| DE60216453T2 (de) | 2007-09-20 |
| CY1105822T1 (el) | 2011-02-02 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| DE602004026113D1 (de) | Glp-1-verbindungen | |
| UY27787A1 (es) | Activadores cicloalquil sustituidos y cicloalquil oxigenados de glucoquinasa. | |
| GEP20063908B (en) | Human glucagon-like-peptide-1 mimics and their use in the treatment of diabetes and related conditions | |
| ATE193541T1 (de) | Insulinotropes hormon | |
| DE102004014983A1 (de) | Rekombinante Polypeptide der Mitglieder der TNF Ligandenfamilie und deren Verwendung | |
| TR200100600T2 (tr) | İnsülinotropik peptitlerin kullanımı. | |
| MA25567A1 (fr) | Nouvelle composition et son utilisation | |
| SE0301882D0 (sv) | New use I | |
| PT790824E (pt) | Acidos carboxilicos 2,2-dicloroalcanos medicamentos contendo os mesmos e o seu uso para o tratamento da resistencia a insulina | |
| ATE288759T1 (de) | Verwendung von stabilisierten oligonucleotiden zur herstellung von antitumoralen arzneimitteln | |
| SE9201573D0 (sv) | Use of igf-1 | |
| DE69635351D1 (de) | Spinalnadel | |
| ATE346601T1 (de) | Verwendung von antidiabetika zur herstellung eines vernarbungsfördernden arzneimittels | |
| TR199902980T2 (xx) | Diabetin tedavisi i�in leptin antagonistlerinin kullan�m�. | |
| YU29002A (sh) | Tretiranje emfizema primenom rar selektivnih retinoid agonista | |
| DE60316152D1 (de) | Prozess zur herstellung von pioglitazon via verschiedene zwischenstufen | |
| ATE174629T1 (de) | Herstellung von proteinen mittels protein 7b2 | |
| DE69734574D1 (de) | Rekombinante adenovirenvektoren zur gentherapie der menschlichen krebse | |
| UA81649C2 (ru) | Эфиры карбаминовой кислоты, которые имеют антихолинергическое действие | |
| ATE344223T1 (de) | Vitamin d-analoge | |
| DE69728654D1 (de) | Verwendung von il-7 zur behandlung von autoimmunkrankheiten, insbesondere insulinabhängigem diabetes mellitus | |
| ATE345791T1 (de) | Verwendung von anethol-dithiolethion zur vorbeugung von lungenkrebs | |
| UY26366A1 (es) | Uso de (+)- tramadol, o demetiltramadol y/o (+) -o- demetiltramadol, o - desmetil-n-monodesmetil-tramadol, y/o (+) -o desmetil-n-monodesmetil-tramadol para la preparacion de un medicamento para el tratamiento de urgencia urinaria incrementada o incon | |
| CO4960663A1 (es) | Fumarato de 2-(-3-(4-(2-t-butil-6-trifluorometilpirimidin- 4-il)piperazin-1-il) propilmecapto)pirimidin-4-ol | |
| ATE163856T1 (de) | Verwendung eines direkten inhibitors von thrombin zur herstellung eines arzneimittels mit thrombolytischer aktivität |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| UEP | Publication of translation of european patent specification |
Ref document number: 1397124 Country of ref document: EP |